Ultragenyx Pharmaceutical Inc., of Novato, Calif., reported longer-term safety and efficacy data from the first dose cohort of a phase I/II trial testing the 2 × 10^12 GC/kg dose of its gene therapy, DTX-301, in patients with ornithine transcarbamylase deficiency.